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Introduction
Hypoglycemia in the patient without 
diabetes mellitus is uncommon.
1
 An initial 
evaluation of hypoglycemia begins with 
confirming Whipple’s triad which includes: 
the presence of sympathoadrenal and 
neuroglycopenic symptoms, documented 
low plasma glucose concentration, and 
resolution of symptoms when plasma 
glucose is raised.
2
 Hypoglycemia secondary 
to hydroxychloroquine previously has been 
documented in humans.
3,4
 We describe a 
case of severe hyperinsulinemic 
hypoglycemia in a patient initiated on 
hydroxychloroquine therapy. 
 
Case Report 
A 66-year-old female with a complex 
medical history including rheumatoid 
arthritis and pyoderma gangrenosum, but 
without known history of either diabetes 
mellitus or exposure to glucose lowering 
medications, was admitted to the hospital for 
evaluation and management of anasarca.  
While hospitalized, the patient was initiated 
on hydroxychloroquine for management of 
her rheumatologic disorders. Within hours 
of her first dose of hydroxychloroquine, the 
patient developed hypoglycemia with a 
glucose value of 28 mg/dL on serum 
measurement. She was symptomatic with 
diaphoresis, tremors, and confusion. Her 
symptoms resolved with administration of 
dextrose.   
Additional pertinent medical history 
included a long-standing history of chronic 
exogenous steroid use due to her 
rheumatologic disorders.  At the time of this 
hypoglycemic event, the patient was placed 
on stress dose steroids (hydrocortisone 
100mg IV q 8 hours). She did not have a 
history of prior bariatric surgery, renal 
insufficiency, uncontrolled hypothyroidism, 
or findings to suggest an infectious etiology 
of hypoglycemia. 
Although standard hypoglycemic 
laboratory was not obtained with the initial 
hypoglycemic event, the patient had 
multiple additional episodes of symptomatic 
hypoglycemia, despite receiving stress dose 
steroids, at which time a standard 
hypoglycemic laboratory evaluation was 
undertaken. Diagnostic laboratory captured 
at the time of a recurrent hypoglycemic 
event was consistent with hyperinsulinemic 
hypoglycemia (Table 1). 
In light of hyperinsulinemic hypo-
glycemia without known exposure to oral 
hypoglycemic agents, a computed tomo-
graphy scan of the abdomen was obtained. 
This study was negative for any evident 
pancreatic mass and given the temporal 
relationship of administration of hydroxy-
chloroquine to development of hypo-
glycemia, no further imaging was obtained. 
Due to prior case reports associating 
hydroxychloroquine with hypoglycemia, 
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Table 1.  Hypoglycemic laboratory evaluation. 
 
this medication was discontinued prior to 
any additional doses being administered. 
Hypoglycemia persistently recurred over an 
approximately ten-hour period following the 
first dose of hydroxychloroquine, then it 
resolved without recurrence, confirming 
hydroxychloroquine as the causative agent. 
The patient was followed in the hospital 
setting for an additional four days without 
recurrence of hypoglycemia. In addition, she 
was seen in ambulatory follow-up within 
one month of discharge without recurrent 
events. 
 
Discussion 
Hypoglycemia is a rare, but well 
recognized, adverse effect of treatment with 
anti-malarial agents including hydroxy-
chloroquine and chloroquine.
3
 Hypo-
glycemia secondary to hydroxychloroquine 
has been documented previously in the 
medical literature, both in patients with 
diabetes on stable doses of glucose lowering 
drugs as well as patients without a prior 
history of diabetes and on no hypoglycemic 
agents.
3,6 
The mechanism of hydroxychloroquine-
induced hyperinsulinemic hypoglycemia has 
been inferred from studies on chloroquine, 
which is structurally similar. In the 
streptozocin-treated type 1 diabetic rat 
model, chloroquine led to higher levels of 
insulin with concomitant drops in blood 
glucose.
9
 Additionally, a second study has 
shown an increase in the level of plasma 
immunoreactive insulin in rats treated with 
chloroquine.
10
 This is thought to be due to 
enhanced insulin secretion from beta cells,
10
 
as well as inhibition of insulin degradation 
by chloroquine.
11
  
Animal studies have shown that 
hydroxychloroquine increases insulin levels 
in diabetic rats, thereby decreasing serum 
glucose levels. This increase in insulin also 
has been found to be concentration-
dependent to the amount of hydroxy-
chloroquine administered.
12
  
The glycemic effects of hydroxy-
chloroquine in humans have been well-
described in several clinical studies 
evaluating its use in treatment and 
prevention of diabetes mellitus.  It improves 
glycemic control in individuals with 
diabetes with and without autoimmune 
diseases.
13,14
 It significantly decreased 
glycated hemoglobin and fasting glucose in 
patients with type 2 diabetes mellitus that 
previously had been non-responsive to 
sulfonylureas and other medications for 
diabetes.
13-15
 Hydroxychloroquine has been 
associated with a decreased risk of 
development of diabetes mellitus in patients 
with rheumatologic disorders.
16-18 
 
Conclusion 
We described a case of severe and 
persistent hyperinsulinemic hypoglycemia 
with initiation of hydroxychloroquine in a 
patient without diabetes mellitus. This case 
report adds to the sparse literature 
surrounding this important clinical topic.  
Based on animal data, the cause of 
hydroxychloroquine-induced hyperinsulin-
emic hypoglycemia is thought to occur via 
  
Glucose Insulin C-peptide Proinsulin Hypoglycemic 
Screen 
Reference Ranges 
for Endogenous 
Hyperinsulinemia 
< 55 
mg/dL 
> 3.0 
U/mL 
> 0.2 
nmol/L 
> 5 
pmol/L 
Negative 
Patient Values 53 
mg/dL 
102.9 
U/mL 
6.0 
nmol/L 
330 
pmol/L 
Negative 
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two different mechanisms:  enhanced insulin 
secretion from beta cells as well as 
inhibition of insulin degradation. The 
proposed mechanisms behind hydroxy-
chloroquine-induced hypoglycemia are 
consistent with the laboratory results of our 
patient. Although the literature supporting 
the role of hydroxychloroquine as an agent 
associated with hyperinsulinemic hypo-
glycemia is limited, there is mounting 
evidence of hydroxychloroquine’s role in 
diabetes prevention in patients’ with 
rheumatologic disorders. Healthcare 
providers and patients should we aware of 
the potential for modulation of glycemic 
status with this class of medications. 
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